Last Update 23 Jun 26

NTLA: Phase 3 Gene Editing Readouts And FDA Progress Will Drive Upside

Analysts have lifted their price target on Intellia Therapeutics to $17 from $13, reflecting updated views on the company in the context of a stronger biotech sector and expectations for continued merger-and-acquisition and IPO activity.

Analyst Commentary

Recent moves around Intellia Therapeutics show a mix of optimism and caution, with several firms revisiting their models and adjusting price targets in both directions as they reassess sector conditions and company specific execution risk.

Bullish Takeaways

Bullish analysts highlight the improved tone across biotech, pointing to sector returns cited at 11% year to date and using that backdrop to support higher price targets for Intellia Therapeutics.
Some recent upward target revisions suggest confidence that Intellia Therapeutics can execute on its pipeline and milestones well enough to justify a higher valuation range, even if ratings stay more neutral such as Market Perform.
Positive views on continued M&A and IPO activity in biotech are seen as a potential support for asset values, which bullish analysts factor into their target assumptions for Intellia Therapeutics.
Analysts who have raised targets recently are treating changes at the FDA as a constructive factor for earlier stage companies, which can feed into more supportive scenarios for Intellia Therapeutics programs over time.

Bearish Takeaways

There are also bearish analysts cutting price targets, which signals concern that prior expectations for Intellia Therapeutics may have been too optimistic relative to current clinical or commercial visibility.
Target reductions suggest some caution around execution risk, including timing and outcomes for key programs, which in turn can limit how much valuation upside these analysts are willing to underwrite.
The reference to coverage being down 3% on a cap weighted basis, even as smaller companies have outperformed, highlights the risk that larger positions in the space, including Intellia Therapeutics, may not fully track sector strength if stock specific questions remain.
Mixed target moves across different firms point to an uneven conviction level, with some bearish analysts focusing on the possibility that company fundamentals may not fully support the higher targets suggested by more optimistic peers.

What’s in the News for Intellia Therapeutics

Intellia Therapeutics reported positive global Phase 3 HAELO trial results for its in vivo CRISPR therapy lonvoguran ziclumeran (lonvo-z) in hereditary angioedema, with an 87% reduction in mean monthly attacks versus placebo and 62% of patients attack free during the evaluation period, according to multiple sources.
The company initiated a rolling Biologics License Application with the FDA for lonvo-z, supported by Regenerative Medicine Advanced Therapy designation. Management indicated an aim to complete the filing in the second half of 2026 and is preparing for a potential U.S. launch in the first half of 2027, pending review outcomes.
Additional Phase 3 HAELO data for lonvo-z were presented in a late breaking oral session at the European Academy of Allergy & Clinical Immunology 2026 congress and published in the New England Journal of Medicine, reinforcing interest in Intellia Therapeutics’ CRISPR platform, per company disclosures.
The FDA lifted clinical holds on Intellia Therapeutics’ MAGNITUDE Phase 3 trials for nexiguran ziclumeran in transthyretin amyloidosis, allowing screening to resume and reducing regulatory uncertainty around this second late stage in vivo gene editing program, according to recent news reports.
Intellia Therapeutics completed and upsized a follow on equity offering of about US$180.0 million, following a prior US$150.0 million filing. This extended its reported cash runway into at least 2028, while introducing some dilution and lock up agreements for common stock, stock options and restricted stock units.

Valuation Changes for Intellia Therapeutics

Fair Value: $26.63 is unchanged, indicating no adjustment to the central valuation estimate for Intellia Therapeutics based on the latest inputs.
Discount Rate: risen slightly from 7.14% to 7.22%, implying a modestly higher required return being applied to future cash flows.
Revenue Growth: increased from 134.05% to 139.59%, reflecting a higher assumed growth rate in future revenue.
Net Profit Margin: increased from 5.51% to 8.54%, indicating a higher assumed level of long-term profitability on future earnings.
Future P/E: fallen significantly from 119.92x to 72.32x, pointing to a lower valuation multiple being applied to projected earnings even as other assumptions have shifted.

26 views

Key Takeaways

Accelerated clinical progress and expanding market opportunities position Intellia for earlier commercialization and significant long-term revenue growth.
Improved financial discipline and strong clinical validation support sustainable margins, enhanced payer acceptance, and recurring revenue from commercialization and partnerships.
Competitive pressures, high development costs, pipeline concentration, and reimbursement barriers threaten Intellia's growth, profitability, and ability to sustain its technological edge over time.

Catalysts

About Intellia Therapeutics

A clinical-stage gene editing company, focuses on the development of curative genome editing treatments.What are the underlying business or industry changes driving this perspective?

Growing patient and physician enthusiasm for Intellia's lead in vivo CRISPR therapies is driving faster-than-expected enrollment across multiple late-stage clinical trials (including an expanded 1,200-patient ATTR cardiomyopathy study and strong uptake in HAE), positioning the company to achieve meaningful clinical readouts and regulatory milestones ahead of prior guidance-this advances timelines to potential commercialization, driving long-term revenue growth prospects.
The sustained expansion of the addressable market for Intellia's programs is reinforced by demographic trends-especially aging populations and the continued rise in genetic and chronic conditions like ATTR amyloidosis and HAE-supporting higher future patient volumes and underpinning potential multi-launch revenue inflection points.
Improving financial discipline, as evidenced by successful restructuring, declining GAAP operating expenses (~10% reduction YoY), and a robust cash runway into the first half of 2027, enables Intellia to absorb increased R&D investment, advance pipeline expansion, and build out commercial infrastructure without dilutive fundraising, supporting protection of net margins and improving future earnings visibility.
Strengthening real-world validation of the company's platform-with mature clinical data showing durable, attack-free results in HAE and deep TTR reductions plus positive functional outcomes in ATTR-should bolster pricing power, enhance payer acceptance, and create leverage for value-based reimbursement, directly benefiting gross margins and long-term profitability.
Rapid technological and regulatory advancements in gene-editing-including increased healthcare investments, accelerating review pathways, and support for first-in-class CRISPR therapies-create a favorable environment for Intellia's platform to secure approvals, forge additional partnership/licensing opportunities, and achieve sustainable, recurring non-dilutive revenues through both commercialization and collaborations, increasing top-line growth and earnings potential.

Intellia Therapeutics Earnings and Revenue Growth

Intellia Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Intellia Therapeutics's revenue will grow by 139.6% annually over the next 3 years.
Analysts assume that profit margins will increase from -597.0% today to 8.5% in 3 years time.
Analysts expect earnings to reach $77.6 million (and earnings per share of $0.76) by about June 2029, up from -$394.6 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $2.5 billion in earnings, and the most bearish expecting $-550.3 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 72.4x on those 2029 earnings, up from -5.5x today. This future PE is greater than the current PE for the US Biotechs industry at 16.8x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.22%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Mounting competition from alternative gene therapy and RNAi approaches-including established and newly launched therapies in ATTR amyloidosis and HAE-could limit nex-z and lonvo-z's market share and weaken Intellia's pricing power, impacting long-term revenue growth and gross margins.
Reliance on major late-stage clinical trial results for limited lead programs (nex-z, lonvo-z) creates revenue concentration risk; any regulatory, clinical, or safety setbacks could significantly delay or diminish future earnings and long-term profitability.
High R&D expenses and ongoing cash burn, combined with no near-term commercial product revenues, raise the risk of shareholder dilution or funding constraints, potentially pressuring net margins and earnings despite current cash runway guidance.
Payer scrutiny and reimbursement challenges for costly, potentially one-time gene-editing therapies-especially in crowded indications-could limit uptake, slow commercial ramp, and jeopardize expected revenue streams.
Advances in other gene editing or treatment modalities (such as prime editing, base editing, or more effective RNAi) could erode Intellia's technological lead, making its CRISPR platform less differentiated over the long term, which would negatively affect revenue growth and long-term valuation.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $26.63 for Intellia Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $95.0, and the most bearish reporting a price target of just $8.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $909.0 million, earnings will come to $77.6 million, and it would be trading on a PE ratio of 72.4x, assuming you use a discount rate of 7.2%.
Given the current share price of $15.67, the analyst price target of $26.63 is 41.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Intellia Therapeutics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Paused Trials Will Drive Rebound After Resolution Of Safety Concerns